Discovery of anti-SARS-CoV-2 agents from 38 Chinese patent drugs toward respiratory diseases via docking screening
The 2019 novel coronavirus (2019-nCoV) causes novel coronavirus pneumonia (NCP). Given that approved drug repurposing becomes a common strategy to quickly find antiviral treatments, a collection of FDA-approved drugs can be powerful resources for new anti-NCP indication discoveries. In addition to s...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Maximum Academic Press
2023-02-01
|
| Series: | Medicinal Plant Biology |
| Subjects: | |
| Online Access: | https://www.maxapress.com/article/doi/10.48130/MPB-2023-0009 |